Search

Chronic non cirrhotic extrahepatic portal vein obstruction (EHPVO) refers to the cavernomatous transformation of the portal vein (the so-called “portal cavernoma”) which occurs following acute thrombosis of the portal vein in the absence of recanalization. In adults, EHPVO mainly occurs following thrombosis, while in children it may be related to congenital malformations and/or neonatal umbilical venous catheterization. However, 50% of the cases of EHPVO remain idiopathic [1]. Risk factors and associated diseases should be investigated (chapter 1). Indeed, the presence of a thrombophilic alteration, in particular myeloproliferative neoplasm impacts prognosis and determine a causal treatment.

At the time of the growing obesity epidemic worldwide, liver transplantation (LT) and metabolic syndrome are closely linked: non-alcohol-related fatty liver disease (NAFLD) is one of the leading indications for liver transplantation, and metabolic syndrome can also appear after liver transplantation, in relation to immunosuppressive medications and weight gain, whatever was the initial liver disease leading to the indication of LT. Therefore, the role of bariatric surgery (BS) is important due to its longer-lasting effect and efficacy. We performed a retrospective review of all 50 adult French liver transplant recipients who had a history of bariatric surgery, including 37 procedures before transplantation, and 14 after. There were three significantly different characteristics when comparing pre-and post-LT BS: patients were older (at the time of BS), presented more frequently arterial hypertension (at the time of LT), and the proportion of NAFLD as initial liver disease leading to LT was lower, in the post-LT group. Regarding pre-LT BS, in one case BS was complicated by liver failure leading to the rapid indication of LT; it was the single patient for whom the delay between BS and LT was less than 1 year; there was no patient who specifically underwent BS for the purpose of LT listing.

•Fibrosing cholestatic hepatitis is a rare and very severe form of HCV recurrence after liver transplantation.•Prognosis of HCV recurrence after liver transplantation has been dramatically modified because of direct antivirals.•Histological outcome of 17 patients has been studied.•Fibrosis stage worsened in the majority of patients with fibrosing cholestatic hepatitis despite HCV cure.

•After liver transplantation (LT), de novomalignancies are one of the leading causes of late mortality.•Risk factors of de novomalignancies in a large cohort of LT recipients (n=11004) are described using Fine and Gray competing risks regression analysis.•The overall incidence of de novo malignancies was 13.45%.•Were significant risk factors for de novomalignancy: recipient age, male gender, non-living donor, a first LT and the type of initial liver disease.•Initial immunosuppressive regimen had no significant impact.

•Coronavirus disease-2019 (Covid-19) is an ongoing global pandemic of major concern.•Available data on clinical presentation and prognosis in liver transplant (LT) recipients remains limited.•Disease presentation, immunosuppression management, outcomes, prognostic factors in 104 French LT recipients with Covid-19 are reported.•The composite endpoint of severe Covid-19 within 30 days after diagnosis was reached by 33.0% of the adult patients.•The 30-day mortality rate of adult patients was 20.0%, and 28.1% for hospitalized patients.

•The possible diseases of the liver graft after transplantation are multiple and often intertwined.•Radiological methods are the standard for the diagnosis of vascular and biliary complications of transplantation.•Non-invasive evaluation of the liver graft lesions has been poorly evaluated, apart from the recurrence of hepatitis C.•Liver biopsy remains the gold standard for evaluating graft lesions in the majority of cases.